Neorx Corporation

Kasina Laila Innova Pharmaceuticals Private Limited

Poniard Pharmaceuticals, Inc.

Other

University of Utah Research Foundation

University of Wa

Sudhakar Kasina

Alan R Fritzberg

Ananthachari Srinivasan

John M Reno

Linda M Gustavson

Rama Raju Gokaraju

David John Grainger

Venkateswarlu Somepalli

James C Metcalfe

Daniel S Wilbur

Ganga Raju Gokaraju

Trimurtulu Golakoti

Jean-Luc VanderHeyden

Jeffrey N Fitzner

Tripuraneni N Rao

Kiran Bhupathiraju

Venkata Kanaka Ranga Raju Gokaraju

Venkata Krishna Raju Alluri

Louis J Theodore

Paul G Abrams

Jonathan F Tait

James A Sanderson

David S Jones

Krishanu Sengupta

Jean-Luc E Vanderheyden

Sengupta Krishanu

Donald B Axworthy

Damon L Meyer

Eric K Yau

Scott Stoll Graves

Alan Fritzberg

Kiran Bhuphatiraju

Dennis L Johnson

D Mark Gleave

The invention discloses 4-(arylamino)selenophenopyrimidine derivatives of formula (I), hydrates, solvates, isomers, or pharmaceutically acceptable salts thereof; process for their preparation and methods of treating or inhibiting or controlling a cell proliferative disorders, particularly cancer using said compounds. Pharmaceutical compositions comprising 4-(arylamino)selenophenopyrimidine derivatives of formula (I) are useful for the treatment, inhibition, or control of cancer. 

Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof

The invention relates toF-labeled compounds of formula (I), hydrates, isomers, or pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions. The invention relates to the methods of diagnosing kidney function in humans by PET imaging. 

F-18 radiolabeled compounds for diagnosing and monitoring kidney function

Selenophene compounds of formula (I) are described herein. In the compounds of Formula (I), ring A is a 6-membered aromatic fused ring, optionally containing one, two or three nitrogen atoms; a 5-membered heteroaromatic fused ring; or a mono- or bicyclic saturated heterocyclic fused ring having at least one ring member selected from the group consisting of N, O, S, SO and SO; Y in ring B is nitrogen or substituted carbon; X is NR, O, S, S(O), or S(O). R, R, R, R, and Rare defined in the specification. Selenophene compounds of formula (I) may be used in methods of treating cell proliferative disorders, particularly cancer. Pharmaceutical compositions containing selenophene compounds of formula (I) may be used for treatment, inhibition, or control of cancer. 

Substituted 4-(selenophen-2(or-3)-ylamino)pyrimidine compounds and methods of use thereof

The present invention discloses triazene analogs of the general formula (I) and formula (II), their tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts thereof for the metastatic malignant melanoma and other cancers including but not limited to lymphomas, sarcomas, carcinomas, and gliomas. The invention further discloses a process for the preparation of the above said triazene analogs of formula (I) and formula (II), and their pharmaceutically acceptable compositions.

Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R, R, R, R, and Rare as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.

Radiolabeled annexins

The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.

Bridged aromatic substituted amine ligands with donor atoms

The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.

Compounds and therapies for the prevention of vascular and non-vascular pathologies

Steroid receptor analogs having good binding affinity for steroid receptors and &ldquo;binding arms&rdquo; for chelation to metal species such as radionuclides are prepared with all carbon backbones. The analogs very closely approximate the geometries present in natural steroids which are important for effective binding to receptor sites. In addition, metal species binding arms are strategically incorporated into the analog structure in a manner that does not disrupt the analog's receptor binding efficacy. Furthermore, the metal species binding arms may be designed to chelate one or more radionuclides, including radionuclides effective in diagnostic or therapeutic applications. With incorporation of an appropriate steroid receptor binding group, these metal species-bound analogs may be used, for example, to bind androgen receptor sites in the diagnosis or treatment of prostate cancer, or estrogen receptor sites in the diagnosis or treatment of breast and ovarian cancers.

Non-steroidal compounds for steroid receptors and uses relating thereto

Growing community of inventors

Mercer Island, WA, United States of America

Sudhakar Kasina